MW-313
Chronic Kidney Disease, Cardiovascular Disease
PreclinicalActive
Key Facts
Indication
Chronic Kidney Disease, Cardiovascular Disease
Phase
Preclinical
Status
Active
Company
About Mwyngil Therapeutics
AI‑powered biotech creating oral NLRP3 and GPR75 small‑molecule drugs for obesity and CKD.
View full company profile